Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
- 1 March 1995
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 75 (8) , 559-562
- https://doi.org/10.1016/s0002-9149(99)80616-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1994
- Preprocedural anticoagulation does not reduce angioplasty heparin requirementsAmerican Heart Journal, 1993
- Arterial injury and the enigma of coronary restenosisJournal of the American College of Cardiology, 1992
- HeparinNew England Journal of Medicine, 1991
- Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.Heart, 1990
- Adequate heparinization during PTCA: Assessment using activated clotting timesCatheterization and Cardiovascular Diagnosis, 1989
- Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate.Journal of Clinical Investigation, 1989
- Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: Temporal relationship to discontinuation of anticoagulationAmerican Heart Journal, 1988
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985